Efficacy and Safety of Pharmacotherapy in Cancer-Related Anorexia and Cachexia Symptoms: An Updated Systematic Review and Network Meta-Analysis
Abstract
Introduction: Cancer-associated cachexia syndrome (CACS) is a complex condition characterized by anorexia, weight loss, and muscle wasting, significantly affecting quality of life and treatment outcomes. The comparative efficacy and safety of pharmacological treatments remain uncertain.
Methods: A systematic review and network meta-analysis were conducted using randomized clinical trials (RCTs). Three databases were searched for studies published between 2000 and 2024. The analyzed outcomes included absolute weight gain, improvement in the anorexia-cachexia subscore (ACS), and the risk of serious adverse events (AEs).
Results: Nine studies involving 1,505 participants were analyzed. Olanzapine demonstrated the most significant weight gain (MD 4.6 kg, 95% CI: 0.82–8.38), while ponsegromab 400 mg and anamorelin 100 mg were effective in maintaining weight, with gains of 3.26 kg (95% CI: 2.35–4.17) and 2.38 kg (95% CI: 1.82–2.94), respectively. However, the network meta-analysis did not confirm the superiority of olanzapine over ponsegromab or anamorelin. Mirtazapine showed limited benefits in weight gain. Regarding ACS, olanzapine demonstrated the highest efficacy, with significant improvement compared to ponsegromab 400 mg (MD 6.5, 95% CI: 1.3–11.7), anamorelin 100 mg (MD 6.9, 95% CI: 1.6–12.1), mirtazapine 15 mg (MD 10.0, 95% CI: 5.8–14.2), ponsegromab 200 mg (MD 10.3, 95% CI: 6.1–14.5), and anamorelin 50 mg (MD 10.3, 95% CI: 5.1–15.4), confirming its superior ACS improvement…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,505 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.